HCPCS Code Applications and Approvals: April 2025
Quarterly archive · CMS Level II HCPCS48 coding decisions took effect April 1, 2025
These are the Centers for Medicare and Medicaid Services (CMS) Level II HCPCS drug coding decisions from the Fourth Quarter 2024 coding cycle, which took effect April 1, 2025.
For the newest decisions, see the current HCPCS code applications and approvals.
CMS Level II HCPCS Drug Coding Decisions
Does not include Q4 skin repair and wound codes.
How to Read This Table
- Action
- CMS decision on the application — establish a new code, revise an existing descriptor, reinstate a code, or discontinue one. See the glossary.
- Code Change
- Where CMS retires a code in favor of another, the new code shows the code it replaces and the retired code shows its replacement.
- 505(b)(2) and Biosimilar
- Tags beside the drug name mark products approved under the FDA 505(b)(2) pathway and biosimilars.
- Effective
- First date of service on which the code may be billed. Codes effective before this quarter reflect retroactive establishment; codes effective after it are decisions CMS scheduled for a later quarter.
April 2025
| HCPCS | Drug & Descriptor | Company | Code Change | Action | Effective |
|---|---|---|---|---|---|
| A9611 | FLYRCADO Flurpiridaz f 18, diagnostic, 1 millicurie | GE Healthcare Intravenous | — | Establish | |
| J0281 | Aminocaproic Acid 505(b)(2) Injection, aminocaproic acid, 1 gram | — | — | Establish | |
| J1072 | AZMIRO 505(b)(2) Injection, testosterone cypionate (azmiro), 1 mg | Azurity Pharmaceuticals, Inc. Intramuscular | — | Establish | |
| J1094 | Decadron-LA Injection, dexamethasone acetate, 1 mg | — | — | Discontinue | |
| J1271 | Doxycycline Hyclate 505(b)(2) Injection, doxycycline hyclate, 1 mg | — | — | Establish | |
| J1299 | Eculizumab Injection, eculizumab, 2 mg | — | ReplacesJ1300 | Establish | |
| J1300 | Eculizumab Injection, eculizumab, 10 mg | — | Replaced byJ1299 | Discontinue | |
| J1308 | Famotidine 505(b)(2) Injection, famotidine, 0.25 mg | — | — | Establish | |
| J1808 | Folic Acid 505(b)(2) Injection, folic acid, 0.1 mg | — | — | Establish | |
| J1810 | Pepaxto Injection, droperidol and fentanyl citrate, up to 2 ml ampule | — | — | Discontinue | |
| J1890 | Keflin Injection, cephalothin sodium, up to 1 gram | — | — | Discontinue | |
| J1938 | Furosemide 505(b)(2) Injection, furosemide, 1 mg | — | ReplacesJ1940 | Establish | |
| J1940 | Furosemide Injection, furosemide, up to 20 mg | — | Replaced byJ1938 | Discontinue | |
| J2351 | OCREVUS ZUNOVO Injection, ocrelizumab, 1 mg and hyaluronidase-ocsq | Genentech Inc. Subcutaneous | — | Establish | |
| J2428 | ERZOFRI 505(b)(2) Injection, paliperidone palmitate extended release (erzofri), 1 mg | Luye Pharma USA Ltd. Intramuscular | — | Establish | |
| J2804 | Rifampin 505(b)(2) Injection, rifampin, 1 mg | — | — | Establish | |
| J2865 | Sulfamethoxazole 5 Mg and Trimethoprim 1 Mg 505(b)(2) Injection, sulfamethoxazole 5 mg and trimethoprim 1 mg | — | — | Establish | |
| J7521 | Tacrolimus Tacrolimus, granules, oral suspension, 0.1 mg | — | — | Establish | |
| J9024 | TECENTRIQ HYBREZA Injection, atezolizumab, 5 mg and hyaluronidase-tqjs | Genentech Inc. Subcutaneous | — | Establish | |
| J9037 | BLENREP Injection, belantamab mafodotin-blmf, 0.5 mg | GSK PLC | — | Discontinue | |
| J9038 | NIKTIMVO Injection, axatilimab-csfr, 0.1 mg | Incyte Corporation Intravenous | — | Establish | |
| J9054 | BORUZU 505(b)(2) Injection, bortezomib (boruzu), 0.1 mg | Amneal Pharmaceuticals, Inc. Intravenous | — | Establish | |
| J9073 | Cyclophosphamide 505(b)(2) Injection, cyclophosphamide (dr. reddy's), 5 mg | Dr. Reddy's Laboratories Inc. | — | Revise | |
| J9161 | LYMPHIR Injection, denileukin diftitox-cxdl, 1 mcg | Citius Pharmaceuticals Inc. Intravenous | — | Establish | |
| J9247 | Pepaxto Injection, melphalan flufenamide, 1mg | — | — | Discontinue | |
| Q2057 | TECELRA Afamitresgene autoleucel, including leukapheresis and dose preparation procedures, per therapeutic dose | Adaptimmune LLC Intravenous | — | Establish | |
| Q4354 | PalinGen Dual-Layer Membrane Palingen dual-layer membrane, per square centimeter | Amnio Technology | — | Establish | |
| Q4355 | Abiomend Xplus Membrane/Abiomend Xplus Hydromembrane Abiomend xplus membrane and abiomend xplus hydromembrane, per square centimeter | Amnio Technology | — | Establish | |
| Q4356 | Abiomend Membrane/Abiomend Hydromembrane Abiomend membrane and abiomend hydromembrane, per square centimeter | Amnio Technology | — | Establish | |
| Q4357 | XWRAP Plus Xwrap plus, per square centimeter | Applied Biologics, LLC | — | Establish | |
| Q4358 | XWRAP Dual Xwrap dual, per square centimeter | Applied Biologics, LLC | — | Establish | |
| Q4359 | ChoriPly Choriply, per square centimeter | International Tissue Inc. | — | Establish | |
| Q4360 | AmchoPlast FD Amchoplast fd, per square centimeter | LifeCell International Pvt Ltd. | — | Establish | |
| Q4361 | EPIXPRESS Epixpress, per square centimeter | MiMedx Group, Inc. | — | Establish | |
| Q4362 | CYGNUS Disk Cygnus disk, per square centimeter | VIVEX Biologics (Vivex) | — | Establish | |
| Q4363 | Amnio Burgeon Membrane/Hydromembrane Amnio burgeon membrane and hydromembrane, per square centimeter | One BioTech LLC | — | Establish | |
| Q4364 | Amnio Burgeon XPlus Membrane/XPlus Hydromembrane Amnio burgeon xplus membrane and xplus hydromembrane, per square centimeter | One BioTech LLC | — | Establish | |
| Q4365 | Amnio Burgeon Dual-Layer Membrane Amnio burgeon dual-layer membrane, per square centimeter | One BioTech LLC | — | Establish | |
| Q4366 | Dual Layer Amnio Burgeon X-Membrane Dual layer amnio burgeon x-membrane, per square centimeter | One BioTech LLC | — | Establish | |
| Q4367 | AmnioCore SL Amniocore sl, per square centimeter | Stability Biologics | — | Establish | |
| Q5139 | Eculizumab-Aeeb (Bkemv) Biosimilar Injection, eculizumab-aeeb (bkemv), biosimilar, 10 mg | — | Replaced byQ5152 | Discontinue | |
| Q5147 | PAVBLU Biosimilar Injection, aflibercept-ayyh (pavblu), biosimilar, 1 mg | Amgen Inc. Intravitreal/Ophthalmic | — | Establish | |
| Q5148 | NYPOZI Biosimilar Injection, filgrastim-txid (nypozi), biosimilar, 1 microgram | Tanvex BioPharma USA, Inc. Intravenous | — | Establish | |
| Q5149 | ENZEEVU Biosimilar Injection, aflibercept-abzv (enzeevu), biosimilar, 1 mg | Sandoz Inc. Intravitreal | — | Establish | |
| Q5150 | AHZANTIVE Biosimilar Injection, aflibercept-mrbb (ahzantive), biosimilar, 1 mg | Valorum Bio Intravitreal | — | Establish | |
| Q5151 | EPYSQLI Biosimilar Injection, eculizumab-aagh (epysqli), biosimilar, 2 mg | Samsung Bioeps Intravenous | — | Establish | |
| Q5152 | Eculizumab-Aeeb (Bkemv) Biosimilar Injection, eculizumab-aeeb (bkemv), biosimilar, 2 mg | — | ReplacesQ5139 | Establish | |
| Q9999 | OTULFI Biosimilar Injection, ustekinumab-aauz (otulfi), biosimilar, 1 mg | Fresenius Kabi USA, LLC Subcutaneous/Intravenous | — | Establish |
No coding decisions match those filters.
Source: CMS HCPCS application summaries, Fourth Quarter 2024 coding cycle (PDF) . Data current as of October 7, 2026.
Other Quarters
Decisions per quarter since July 2022 · select a bar to open that quarter
